In Brief This Week: Agilent; AB Sciex; Roche; Warnex; Chronix Biomedical | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies said this week that Erasmus Medical Center in Rotterdam, Netherlands, will use the firm's SureSelect XT Human All Exon target enrichment system along with the Agilent Bravo automated liquid-handling platform as part of the Erasmus Rucphen Family study to identify genetic risk factors for some complex genetic disorders. As part of the project, researchers are sequencing the exomes of 1,500 samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.